SABR for Renal Tumours

Official Title

Phase II Study: Stereotactic Ablative Radiation Therapy for Renal Tumours


Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. The usual treatment for this type of cancer is surgery. Considering the most common patients are an average age of 65 and some are not suitable candiates for surgery, there is great interest in non-surgical alternatives for kidney cancer treatments. This study will investigate the use of Stereotactic Ablative Radiosurgery (SABR) for renal tumours. SABR is a non-invasive alternative, which involves delivery of high doses of radiation to the target, while minimizing the risk of injury to the surrounding organs. Patients will be seen before and end of treatmetn and will be followed at 4 month intervals for up to 2 years. During the follow ups, patients will be asked to complete a quality of life questionnaire and will have standard of care imaging.

Trial Description

Primary Outcome:

  • To evaluate the radiation induced renal impairments in patients receiving SABR.
Secondary Outcome:
  • Chronic Kidney Disease Stage Progression
  • 2-year Local recurrence rate
  • Patient Reported Outcomes
  • Incidence of acute and late toxicities

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society